Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 11.17% is 61% below its 5-year average of 28.76%, near the high end of its 5-year range (-1892.19%–67.57%).
103.36% above its 12-month average of -332.38%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 65.69%.
GROSS MARGIN
11.17%
GROSS MARGIN AVG TTM
-332.38%
GROSS MARGIN AVG 3Y
51.45%
GROSS MARGIN AVG 5Y
28.76%
GROSS MARGIN AVG 10Y
16.41%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+103.36%
CURRENT VS 3Y AVG
-78.29%
CURRENT VS 5Y AVG
-61.16%
CURRENT VS 10Y AVG
-31.94%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.51%
median of 521 covered companies
CURRENT VS SECTOR MEDIAN
-75.98%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$120.80M
Gross Margin
11.17%
TTM Avg
-332.38%
3Y Avg
51.45%
5Y Avg
28.76%
Market Cap
$119.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$118.52M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$117.03M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$123.26M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$116.84M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$115.66M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$114.76M
Gross Margin
90.14%
TTM Avg
48.16%
3Y Avg
49.08%
5Y Avg
32.72%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.80M | 11.17% | -332.38% | 51.45% | 28.76% |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | 67.34% | 64.03% | 72.89% | 33.80% |
| BGM Group Ltd. (BGM)vs › | $111.78M | 12.79% | 14.59% | 10.64% | 11.25% |
| Genelux Corporation (GNLX)vs › | $117.03M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| enGene Holdings Inc. (ENGN)vs › | $123.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 90.14% | 48.16% | 49.08% | 32.72% |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | 99.91% | -67.10% | -31.47% | -20.98% |
Gross Margin
11.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 65.69% |
| 2026-03-31 | -1892.19% |
| 2025-12-31 | 43.55% |
| 2025-09-30 | 53.46% |
| 2025-06-30 | 67.57% |
| 2025-03-31 | 61.97% |
| 2024-12-31 | 40.04% |
| 2024-09-30 | 43.48% |
| 2024-06-30 | 48.08% |
| 2024-03-31 | 25.57% |
| 2023-12-31 | -30.25% |
| 2023-09-30 | 57.81% |
| 2023-06-30 | 58.75% |
| 2023-03-31 | 3.37% |
| 2022-12-31 | -1.46% |
| 2022-09-30 | -401.49% |
| 2022-06-30 | 13.08% |
| 2022-03-31 | 65.00% |
| 2021-12-31 | 38.14% |
| 2021-09-30 | -88.01% |
| 2021-06-30 | -19.41% |
| 2021-03-31 | 7.03% |
| 2020-12-31 | -42.35% |
| 2020-09-30 | -8.29% |
| 2020-06-30 | -155.24% |
| 2020-03-31 | -981.25% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
